Literature DB >> 30222369

Drug-induced bone loss: a major safety concern in Europe.

Khac-Dung Nguyen1,2, Bahador Bagheri3, Haleh Bagheri1.   

Abstract

INTRODUCTION: Drug-induced bone loss remains the major cause of vertebral and hip fractures and significantly associated to morbidity and mortality. This article will review the common drugs identified as the causes of bone loss and the risk factors and management in European countries. AREAS COVERED: Beyond glucorticoid - the most cause of osteoporosis, many different drugs could cause harmful skeletal disorders. The antiepileptics, hormonal therapy, GnRH antagonists, aromatase inhibitors are well-known cause of bone loss. Osteoporosis and fractures risk also increased with calcineurin inhibitors, antiretroviral drugs, selective inhibitors of serotonin reuptake, loop diuretics, heparins, oral anticoagulants, high doses of thyroxine and proton pump inhibitors. EXPERT OPINION: Drugs are an important secondary cause of osteoporosis. Healthcare professionals should reassess the requirement for drugs and use the lowest dosage and shortest duration. Lifestyle changes, adequate calcium, vitamin D supplement, appropriate monitoring of bone status and initiating osteoporosis treatment if indicated are recommended when drugs having potential deleterious effects on bone are used, particularly in high risk patients. The update and further studies would provide concluded evidences of controversial drugs induced bone loss and determine the best prevention and treatment strategies.

Entities:  

Keywords:  Adverse drug reaction; bone loss; drug-induced bone loss; osteoporotic fracture

Mesh:

Substances:

Year:  2018        PMID: 30222369     DOI: 10.1080/14740338.2018.1524868

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  5 in total

1.  Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases.

Authors:  Quentin Dardonville; Esther Salguiero; Vanessa Rousseau; Leila Chebane; Jean Luc Faillie; Sophie Gautier; Jean Louis Montastruc; Alfonso Carvajal; Haleh Bagheri
Journal:  Eur J Clin Pharmacol       Date:  2019-08-29       Impact factor: 2.953

Review 2.  Bone-Muscle Crosstalk: Musculoskeletal Complications of Chemotherapy.

Authors:  Brian A Hain; David L Waning
Journal:  Curr Osteoporos Rep       Date:  2022-09-10       Impact factor: 5.163

3.  EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research.

Authors:  L J Seppala; N van der Velde; T Masud; H Blain; M Petrovic; T J van der Cammen; K Szczerbińska; S Hartikainen; R A Kenny; J Ryg; P Eklund; E Topinková; A Mair; L Laflamme; H Thaler; G Bahat; M Gutiérrez-Valencia; M A Caballero-Mora; F Landi; M H Emmelot-Vonk; A Cherubini; J P Baeyens; A Correa-Pérez; A Gudmundsson; A Marengoni; D O'Mahony; N Parekh; F E Pisa; C Rajkumar; M Wehling; G Ziere
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

4.  A novel index to assess low energy fracture risks in patients prescribed antiepileptic drugs.

Authors:  Ola Nordqvist; Olof Björneld; Lars Brudin; Pär Wanby; Rebecca Nobin; Martin Carlsson
Journal:  PLoS One       Date:  2021-08-26       Impact factor: 3.240

5.  Perspectives of patients with depression and chronic pain about bone health after a fragility fracture: A qualitative study.

Authors:  Joanna E M Sale; Monique Gignac; Lucy Frankel; Stephen Thielke; Earl Bogoch; Victoria Elliot-Gibson; Gillian Hawker; Larry Funnell
Journal:  Health Expect       Date:  2021-09-27       Impact factor: 3.377

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.